Key Takeaway
Liraglutide 1.8mg results timeline. Day-by-day expectations at this important dose, weight loss acceleration, metabolic improvements, and what to track during week 3 of treatment.
At liraglutide 1.8mg, most patients see a noticeable acceleration in appetite suppression and early weight loss results. During this one-week titration phase, typical weight loss is 1 to 3 pounds, with cumulative treatment loss reaching 3 to 7 pounds by the end of week 3. For patients who stay at 1.8mg long-term (the Victoza diabetes dose), average weight loss reaches 4 to 5 percent of body weight over 6 months. This is the dose where the medication transitions from preparation to production.
Day-by-Day at 1.8mg
- Day 1 (Treatment Day 15)
- First injection at the 50 percent higher dose. The step up from 1.2mg to 1.8mg is the largest remaining proportional increase. Many patients notice an immediate deepening of appetite suppression, particularly if they inject in the morning and observe reduced hunger at lunch.
- Days 2 to 3
- Steady state at 1.8mg is approximately reached. The full appetite-reducing effect is present. Mild nausea is possible during this window but typically resolves quickly. Eating patterns begin to shift noticeably. Patients report naturally gravitating toward smaller meals.
- Days 4 to 5
- Adaptation solidifies. The appetite effect feels consistent and reliable. Many patients describe this as the first time the medication feels truly "active." Weight loss from reduced food intake is becoming measurable, though still modest.
- Days 6 to 7
- Ready for the next increase to 2.4mg (if on the weight management track). GI symptoms should be resolved. The daily injection is now a well-established routine, three weeks in. liraglutide 1.8mg switching to
Weight Loss Trajectory at 1.8mg
For patients passing through 1.8mg during titration:
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
| Treatment Week | Dose | Cumulative Weight Change |
|---|---|---|
| Week 1 | 0.6mg | 0-2 lbs lost |
| Week 2 | 1.2mg | 1-4 lbs lost |
| Week 3 | 1.8mg | 3-7 lbs lost |
The acceleration at 1.8mg is meaningful. Most patients lose more in week 3 than in either of the first two weeks. This reflects the dose crossing into the therapeutic range for appetite suppression.
For patients staying at 1.8mg long-term (diabetes patients), the trajectory looks different:
- Month 1: 3 to 5 pounds lost
- Month 3: 6 to 10 pounds total
- Month 6: 8 to 14 pounds total (approximately 4 to 5 percent of starting body weight)
- Month 12: Weight stabilizes at the new lower level for most patients
Non-Scale Results at 1.8mg
By week 3, patients commonly report improvements beyond weight:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Reduced food preoccupation: Less time thinking about what to eat next, fewer intrusive food thoughts, easier to pass by the break room without grabbing a snack
- Blood sugar stability: Fasting glucose readings improve. Post-meal glucose spikes are blunted. Patients with prediabetes or diabetes may see their first significant improvements.
- Better sleep: Some patients report improved sleep quality, possibly related to reduced late-night eating, lower blood sugar variability, and initial weight loss
- Improved confidence: The combination of early weight loss and tangible appetite control provides psychological momentum that supports continued adherence
How 1.8mg Results Predict Full-Dose Outcomes
Research suggests that early response to liraglutide is a reasonable predictor of long-term outcomes:
- Patients who lose 4 percent or more of body weight by week 16 (at the full 3.0mg dose) are considered "early responders" and tend to achieve the best long-term results
- Your response at 1.8mg gives early signals. Noticeable appetite reduction and measurable weight loss at this dose suggest strong GLP-1 sensitivity.
- Minimal response at 1.8mg doesn't guarantee poor outcomes at 3.0mg, but it suggests you may need to be especially diligent with diet and exercise to maximize results
Liraglutide early response assessment
Frequently Asked Questions
- Is 1.8mg where I should start evaluating whether liraglutide is working?
- It provides early signals, but the definitive evaluation should wait until you have been at 3.0mg for at least 12 to 16 weeks. At that point, patients who haven't lost at least 5 percent of their body weight are unlikely to achieve significant long-term results, and alternative treatments may be discussed.
- My weight loss stalled at 1.8mg after losing well at 1.2mg. Is that normal?
- Brief stalls during titration are common and usually reflect normal weight fluctuations rather than a true plateau. One week is too short to diagnose a stall. Continue the titration and evaluate results at the full dose.
- Can exercise interfere with my results at 1.8mg?
- Exercise enhances results at every dose. But if you're eating very little and exercising intensely, you may see the scale stall or even go up slightly as your body retains water for muscle repair. This is a positive sign of body composition improvement, not a problem. Continue exercising and eat adequate protein.
- I feel great at 1.8mg. Can I stay here instead of going to 3.0mg?
- Discuss with your prescriber. Some patients achieve acceptable results at intermediate doses. But the full 3.0mg dose produces approximately twice the weight loss of 1.8mg, so you would be leaving significant results on the table. liraglutide 1.8mg how long to stay on
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →